<div class="article">
	<h3>Lacer S.A. of Spain Joins Europe's Drug Consortium</h3>
	<div class="article-info">
		<ul>
			<li>Author: Special to The Wall Street Journal</li>
			<li>Date: 07/13/90</li>
		</ul>
	</div>
	<p class="article-leader">BARCELONA -- The European pharmaceutical industry group,
EuroAlliance, announced the addition of a fourth partner,
Lacer S.A., a closely held pharmaceutical company based here.
   Lacer will represent the Iberian peninsula and joins
EuroAlliance founders Laboratoire L. Lafon representing
France and Belgium; Merckle for Germany, Austria and
Switzerland; and Alfa-Schiaparelli-Wasserman for Italy.</p>
	<div class="article-body"><p>EuroAlliance was established to fund, develop and
distribute selected compounds in Europe. The alliance will
also license compounds from U.S., European and Japanese
companies for the development and launching of new products
throughout Europe.</p>
<p>EuroAlliance has combined annual group sales of more than
$500 million. Total pharmaceutical sales in Europe are
estimated at $30 billion, representing about 18% of the
world-wide market.</p>
<p></p></div>
</div>
